To date, two cytokines have received FDA approval: IL-2 for renal cell carcinoma (RCC) and metastatic melanoma and IFNα for hairy-cell leukemia follicular non-Hodgkin lymphoma and melanoma. Here, IL2 is linked to renal cell carcinoma.